ITGAX and neoplasm: In our work, we also demonstrated the capacity of combined treatment to enhance the CD86 expression in CD11c+MHCII+ dendritic cells and CD11b+MHCII+F4/80+ macrophages into the tumor, accompanied by a decrease in the number of CD11b+Gr-1hi MDSCs.